XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity (Deficit) Statement - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings (Accumulated Deficit)
Adjustment
Adjustment
Additional Paid-In Capital
Adjustment
Retained Earnings (Accumulated Deficit)
Beginning Balance, shares outstanding (in shares) at Dec. 31, 2019   136,713            
Beginning Balance at Dec. 31, 2019 $ 91,765 $ 137 $ 695,066 $ 240 $ (603,678)      
Share-based compensation expense 17,204   17,204          
Issuance of restricted stock awards, net (in shares)   61            
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)   5,278            
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan 63,393 $ 5 63,388          
Repurchase of common stock (in shares)   (7,022)            
Repurchase of common stock (150,117) $ (7) (150,110)          
Equity component of convertible notes (65)   (65)          
Other comprehensive income (loss) (218)     (218)        
Net income 129,085              
Ending Balance, shares outstanding (in shares) at Dec. 31, 2020   135,030            
Ending Balance at Dec. 31, 2020 151,047 $ 135 625,483 22 (474,593) $ (52,564) $ (65,535) $ 12,971
Share-based compensation expense 20,820   20,820          
Issuance of common stock for the induced conversion related to convertible notes (shares)   9,083            
Issuance of common stock for the induced conversion related to convertible notes 13,104 $ 9 13,095          
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)   1,497            
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan 12,536 $ 2 12,534          
Repurchase of common stock (in shares)   (8,112)            
Repurchase of common stock (350,058) $ (8) (350,050)          
Other comprehensive income (loss) (642)     (642)        
Net income 402,710       402,710      
Ending Balance, shares outstanding (in shares) at Dec. 31, 2021   137,498            
Ending Balance at Dec. 31, 2021 196,953 $ 138 256,347 (620) (58,912)      
Share-based compensation expense 24,397   24,397          
Issuance of common stock for the induced conversion related to convertible notes (shares)   1,512            
Issuance of common stock for the induced conversion related to convertible notes 1,693 $ 1 1,692          
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance restricted stock units, net (in shares)   1,077            
Issuance of common stock pursuant to exercise of stock options and vesting of restricted stock units and performance stock units, net and shares issued under ESPP plan 14,050 $ 1 14,049          
Adjustment to Additional Paid in Capital, Capped Call Transaction (69,120)   (69,120)          
Repurchase of common stock (in shares)   (4,933)            
Repurchase of common stock (200,002) $ (5) (199,997)          
Other comprehensive income (loss) (302)     (302)        
Net income 202,129       202,129      
Ending Balance, shares outstanding (in shares) at Dec. 31, 2022   135,154            
Ending Balance at Dec. 31, 2022 $ 169,798 $ 135 $ 27,368 $ (922) $ 143,217